Drug treatment effects on disease progression

被引:113
作者
Chan, PLS [1 ]
Holford, NHG [1 ]
机构
[1] Univ Auckland, Sch Med, Div Pharmacol & Clin Pharmacol, Auckland 1030, New Zealand
关键词
disease progress models; symptomatic; protective; Alzheimer's; Parkinson's; osteoporosis;
D O I
10.1146/annurev.pharmtox.41.1.625
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Degenerative diseases are characterized by a worsening of disease status over time. The rate of deterioration is determined by the natural rate of progression of the disease and by the effect of drug treatments. A goal of drug treatment is to slow disease progression. Drug treatments can be categorized as symptomatic or protective. Symptomatic treatments do not affect the rate of disease progression whereas protective treatments have the ability to slow disease progression down. Many current methods for describing disease progression have two common drawbacks: a linear relationship between time and disease status is assumed, and within- and between-subject variability is ignored. Disease progress models combined with pharmacokinetic-pharmacodynamic models and hierarchical random effects statistical models provide insights into understanding the time course and management of degenerative disease.
引用
收藏
页码:625 / 659
页数:35
相关论文
共 148 条
  • [61] Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
    Hosking, D
    Chilvers, CED
    Christiansen, C
    Ravn, P
    Wasnich, R
    Ross, P
    McClung, M
    Balske, A
    Thompson, D
    Daley, M
    Yates, AJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (08) : 485 - 492
  • [62] AGE AT ONSET AND RATE OF PROGRESSION OF ALZHEIMERS-DISEASE
    HUFF, FJ
    GROWDON, JH
    CORKIN, S
    ROSEN, TJ
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1987, 35 (01) : 27 - 30
  • [63] Two-year treatment of Alzheimer's disease with eptastigmine
    Imbimbo, BP
    Verdelli, G
    Martelli, P
    Marchesini, D
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (02) : 139 - 147
  • [64] Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease
    Jack, CR
    Petersen, RC
    Xu, Y
    O'Brien, PC
    Smith, GE
    Ivnik, RJ
    Tangalos, EG
    Kokmen, E
    [J]. NEUROLOGY, 1998, 51 (04) : 993 - 999
  • [65] RAPIDLY PROGRESSING ATROPHY OF MEDIAL TEMPORAL-LOBE IN ALZHEIMERS-DISEASE
    JOBST, KA
    SMITH, AD
    SZATMARI, M
    ESIRI, MM
    JASKOWSKI, A
    HINDLEY, N
    MCDONALD, B
    MOLYNEUX, AJ
    [J]. LANCET, 1994, 343 (8901) : 829 - 830
  • [66] COMPUTER-SIMULATION AS A TOOL FOR CLINICAL-TRIAL DESIGN
    JONES, DR
    [J]. INTERNATIONAL JOURNAL OF BIO-MEDICAL COMPUTING, 1979, 10 (02): : 145 - 150
  • [67] POSITRON EMISSION TOMOGRAPHY IN DEGENERATIVE DISORDERS OF THE DOPAMINERGIC SYSTEM
    KARBE, H
    HOLTHOFF, V
    HUBER, M
    HERHOLZ, K
    WIENHARD, K
    WAGNER, R
    HEISS, WD
    [J]. JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1992, 4 (02) : 121 - 130
  • [68] COMPARISON OF RATE OF ANNUAL CHANGE OF MENTAL STATUS SCORE IN 4 INDEPENDENT STUDIES OF PATIENTS WITH ALZHEIMERS-DISEASE
    KATZMAN, R
    BROWN, T
    THAL, LJ
    FULD, PA
    ARONSON, M
    BUTTERS, N
    KLAUBER, MR
    WIEDERHOLT, W
    PAY, M
    RENBING, X
    OOI, WL
    HOFSTETTER, R
    TERRY, RD
    [J]. ANNALS OF NEUROLOGY, 1988, 24 (03) : 384 - 389
  • [69] Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia
    Kaye, JA
    Swihart, T
    Howieson, D
    Dame, A
    Moore, MM
    Karnos, T
    Camicioli, R
    Ball, M
    Oken, B
    Sexton, G
    [J]. NEUROLOGY, 1997, 48 (05) : 1297 - 1304
  • [70] A COMPARISON OF BRONCHODILATOR THERAPY WITH OR WITHOUT INHALED CORTICOSTEROID-THERAPY FOR OBSTRUCTIVE AIRWAYS DISEASE
    KERSTJENS, HAM
    BRAND, PLP
    HUGHES, MD
    ROBINSON, NJ
    POSTMA, DS
    SLUITER, HJ
    BLEECKER, ER
    DEKHUIJZEN, PNR
    DEJONG, PM
    MENGELERS, HJJ
    OVERBEEK, SE
    SCHOONBROOD, DFME
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) : 1413 - 1419